ADVFN US – Market Content Editor
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, Markets Cautious Ahead of Fed Rate Decision; General Mills Earnings on Deck
U.S. stock futures were largely flat Wednesday as investors awaited a key Federal Reserve interest rate decision. While the majority of market participants expect a cut in borrowing costs, uncertainty remains over its size and the Fed’s broader economic outlook. Meanwhile, U.K. inflation stayed steady, and packaged foods leader General Mills (NYSE: GIS) is set…
-
STMicroelectronics to Invest $60 Million in Tours Facility Amid Reorganization
STMicroelectronics (NYSE:STM) has announced plans to invest $60 million in its Tours plant in France, aiming to establish a pilot line for cutting-edge semiconductor manufacturing. The Franco-Italian chipmaker said the investment will support the next phase of an advanced production process at the site. In recent months, the company has been relocating older chip production…
-
U.S. Stocks Close Slightly Lower Following Lackluster Trading Session
After ending the previous session mostly higher, stocks showed a lack of direction over the course of the trading day on Tuesday. The Nasdaq and the S&P 500 reached new record intraday highs in early trading but spent the rest of the day lingering near the unchanged line. The major averages eventually ended the day…
-
Warner Bros Discovery Shares Drop Amid Merger Uncertainty and Analyst Downgrade
Warner Bros Discovery (NASDAQ:WBD) saw its stock decline 8% as investors reacted to merger uncertainties and a recent analyst downgrade. CNBC’s David Faber reported that there “may be a bit of a longer wait” for Paramount Skydance to submit a bid for Warner Bros than initially expected, tempering investor optimism that had previously fueled gains…
-
Hims & Hers Stock Drops After FDA Issues Warning on Semaglutide Marketing
Shares of Hims & Hers Health Inc. (NYSE:HIMS) fell 8% Tuesday following a warning letter from the U.S. Food and Drug Administration concerning the company’s marketing claims related to its compounded semaglutide products. The FDA criticized the telehealth firm for making “false or misleading” statements on its website regarding compounded semaglutide offerings. Specific claims flagged…
-
Take-Two Interactive Stock Reaches Record High at $250.68
Take-Two Interactive Software Inc. (NASDAQ:TTWO) hit a new all-time high of $250.68, marking a major milestone for the video game publisher. The company’s market capitalization now stands at $46.1 billion, with analyst price targets ranging from $150 to $285. Over the past year, the stock has surged 63.72%, reflecting investor confidence in Take-Two’s strategic initiatives…
-
Jumia Shares Jump After RBC Upgrade on Supply Chain Improvements
Jumia Technologies AG (NYSE:JMIA), often dubbed the “Amazon of Africa,” saw its stock climb 23% after RBC Capital Markets upgraded the African e-commerce company, citing stronger supply chain operations and easing currency pressures as key growth drivers. Analyst Brad Erickson raised his rating from Sector Perform to Outperform and lifted the price target from $6.50…
-
Apartment Investment and Management Stock Climbs Following $490 Million Boston Property Sale and Special Dividend Announcement
Shares of Apartment Investment and Management Co (NYSE:AIV) rose 3.3% after the company completed the sale of four suburban Boston properties for $490 million and declared a special dividend of $2.23 per share. The dividend is scheduled for payment on October 15, 2025, to shareholders of record as of September 30, 2025, representing a total…
-
Turbo Energy Stock Surges Following $53 Million Energy Storage Deal in Spain
Shares of Turbo Energy SA ADR (NASDAQ:TURB) skyrocketed 240% after the company revealed it had secured a $53 million contract to supply and deploy energy storage solutions for a major industrial construction group in Spain. The deal covers more than ten industrial facilities, where Turbo Energy will install systems totaling 366 MWh over the next…
-
Aptevo Therapeutics Shares Soar Following 100% Remission Rate in AML Trial
Aptevo Therapeutics (NASDAQ:APVO) saw its stock jump 57% on Tuesday after announcing that Cohort 3 of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate. The study is testing mipletamig, Aptevo’s CD123 x CD3 bispecific antibody, alongside venetoclax and azacitidine in newly diagnosed AML patients who are ineligible for…